Dendreon (DNDN -2.1%) resumes trading, giving back most of its gain following the announcement...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN -2.1%) resumes trading, giving back most of its gain following the announcement of the sale of its royalty interest in Victrelis for $125M. The sale appears to be a move to raise cash as sales of its prostrate treatment Provenge are running slower than expected.